A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:
• Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.
• Has a metastatic or locally advanced and unresectable solid tumor.
• Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
• Has an ECOG performance status ≤ 2 at screening.
• Has adequate organ function as defined in the protocol.
Locations
United States
California
The City of Hope National Medical Center
RECRUITING
Duarte
Hoag Memorial Hospital
RECRUITING
Newport Beach
Massachusetts
Dana Farber Cancer Institute
RECRUITING
Boston
Mass General Brigham Cancer Institute
NOT_YET_RECRUITING
Boston
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Texas
The University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Contact Information
Primary
Dr. Eric Rowinsky Chief Medical Officer
erowinsky@oncodrugs.com
(908) 883-0647
Time Frame
Start Date: 2025-12-01
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 171
Treatments
Experimental: Dose Escalation
ST-01156, administered orally once daily for 5 consecutive days followed by 2 days without study drug administration every 7 days
Related Therapeutic Areas
Sponsors
Leads: SEED Therapeutics, Inc.